Zeina Antoun

Zeina Antoun holds an MD degree from the American University of Beyrouth and has an American Board certification in Internal Medicine, and a University Diploma in Infectious Diseases. Between 1994 and 1998, she worked at Bichat, Claude-Bernard Hospital as a full-time clinician in Infectious Diseases and HIV. In 1998, she joined GlaxoSmithKline France, Clinical research unit in Virology, and was then appointed in 2004 as Director, Clinical research in Virology, Therapeutic Vaccines, Oncology and Respiratory diseases. In 2007, Zeina Antoun created a new department dedicated to Early phase research, New domains and Academic alliances, creating many links between GSK R&D groups and French Public research teams. Zeina Antoun is a member of several external working groups at LEEM, ARIIS, Investment funds and other boards. She is also co-author on many publications.

Maurice Chelli

Soon available

Jean Derégnaucourt

D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at UCLA, was recently appointed Exec VP Bus Dev at Pasteur Institute after being CEO of the Medicen Paris Region Biocluster. He also is currently President, VP or Member of various Scientific or Bus Dev Committees. His previous positions were VP Project Management, then VP Chemical and Pharm Dev at Rhone Poulenc Rorer (1990-1998) and later, President of the Pierre Fabre Laboratories R&D (1998-2003). He contributed to the international development and worldwide registration of a dozen of products among them two blockbusters, Clexane and Taxotere. Very recently, FDA approved Fetzimab an antidepressor, he patented a few years ago. For a few years he also moved to an institutional position as Director of Biotechnology at the French Research Ministry (2003-2006). He also was Vice President of the Biotech Company Cellvir which he cofounded in 2008.

Patrick Korman

Patrick Korman joined Myriad Genetics in 2011 and is currently VP Europe Business Development, Market Access and Public Affairs at Myriad Genetics and CEO at Myriad Genetics France. Mr. Korman has been employed in the life sciences industry for more than 25 years.
He served as CEO in a French biotech company, Fluigent, a spin-off of Curie Institute, and prior to that, he was CEO at Alexion Pharmaceutical France from the startup of the company and a Senior Member of Alexion Europe Leadership Team, spending 3 years establishing the business from MAA to pricing and first years of sales. Prior to Alexion, he built an extensive experience of the Pharma industry as VP in different international consulting firms. Mr. Korman has a MA Political Sciences and MBA from HEC.

Antony Lebeau

PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as research engineer (Inserm/Research Institut of Servier), project manager (GIS Prion-Ministry of Research, Inserm Transfert), communication manager (Inserm-Tranfert and Inserm-Transfert Initiative. He joined the French National Research Agency (ANR) as project manager in the of “Health Biology” department, working on Technology Transfer programs (RIB/Biotecs ,TecSan). He currently works as program officer in the ANR department of “Investments for the future and competitiveness”, working in the field of public-private partnerships. Antony Lebeau has been also expert for the European Commission and for the ERC in “Health and Biotechnology” and “Ethic and Governance” fields for the past 8 years.

Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995: Mail Order Pharmacy.
His previous positions were: Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.
Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.

Richard Pleass

Soon available

Frédéric Scaërou

Frédéric Scaërou is Director Scientific Affairs at Ipsen Innovation where he is responsible for identifying, implementing and monitoring key Public/Private scientific partnerships in Oncology which aim to sustain Ipsen R&D innovation.
Before joining Ipsen, Frédéric held various management positions in biopharmaceutical companies, academia and the not-for-profit sector. He worked in discovery research in France (Cytomics Pharmaceuticals) and in the UK (Cyclacel Ltd), in technology transfer (Institut Curie) and was, more recently, the director of research operations and science funding for the largest french cancer charity.
He holds a PhD in Biology and Genetics from the University of Paris VI.

Pascal Touchon

Pascal Touchon has 28 years’ experience in the pharmaceutical industry in Research, Marketing and Sales, General Management and Business Development.
He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa.
As head of Business Development for Servier over the last 4 years, he led the closing of more than 25 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two private company acquisitions and a public offer.
Servier is a private research based pharmaceutical company with sales of 3.9 billion euros worldwide and activities in cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology.
Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.

Ola Winqvist

Immunologist with extensive experience of managing academic research and entrepreneurial experience from founding several start up companies in Life Science.
Education:

• M. D., University of Uppsala 1991
• Ph. D., University of Uppsala 1994
• Post-Doc at Scripps Research Institute, La Jolla, CA, USA 1995-1998
• Associate Professor Experimental Medicine 1999
• Professor Clinical Immunol 2011

Professionnal experience:
I did my PhD on Addison’s disease and my post doc at Scripps research Institute working with antigen processing, presentation and peripheral tolerance mechanisms. I’m now heading a group of 12 persons working with immune mediated disease. I´m presently Professor of cellular immunotherapy and senior consultant heading cellular immunology at the Karolinska University Hospital. Since 2010 I’m the Director of the Karolinska FOCIS center of excellence allowing and since 2013 I’m the director of The Swedish Immunology Society.

Cécile Théard-Jallu

Cécile Théard-Jallu has developed in-depth expertise as an attorney in private practice representing multinational corporations, including major US and European firms and organizations in the R&D and healthcare sectors (public or private research institutions, academics, pharmaceutical laboratories, biotechnology companies, medical equipment manufacturers, service providers, investors, competitiveness clusters and other intermediaries in the field of innovation…) as well as in other industrial sectors such as energy, but also in the field of IT and services.
Cecile focuses primarily on complex transactions including R&D and consortiums, technology transfers, licensing deals and other technological change related projects.
She assists clients with their responses to calls for projects in the R&D and innovation sector in the context of public funding, for instance those linked to future investment programmes (Programme des Investissements d’Avenir) or financial assistance schemes from the Single Inter-Ministry Fund (FUI).
She also advises them on the design, negotiation and enforcement of their commercial or IT contracts.
She worked in Washington DC for over one year as an attorney in private practice, and was also seconded to a global player in the medical equipment sector.
Cécile holds two postgraduate degrees in Business Law (DESS Juriste d’affaires and D.J.C.E., 1995) from the Universities of Nanterre and Montpellier.

Olivier Guth

Olivier Guth is Doctor in Pharmacy from the University of Paris V and holds a MBA from ESGCI – Paris – (Ecole Supérieure de Gestion et de Commerce International).
He has nearly 17 years experiences in the Pharmaceutical industry during which he held different positions in R&D Project management, Business Development and Production.
Olivier GUTH joined MAYOLY-SPINDLER in 2004. He was first Head of Business Development for the CMO part of the Group and then joined the Scientific Direction as the Head of Pharmaceutical Development to manage several R&D programs. Currently Head of Innovation, Evaluation and Project coordination, he is now in charge of the Research and the Evaluation of new Innovated products and R&D partnerships.
Before joining MAYOLY-SPINDLER, he worked for ETHYPHARM and DIAGNOSTICA STAGO as Production Director.
MAYOLY-SPINDLER is a privately owned french company which focuses on Gastroenterology and Dermo-cosmetics fields.